Related Experiment Video
Updated: Jun 25, 2026

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring
Published on: November 13, 2012
Considerations for the use of imaging tools for phase II treatment trials in oncology
Lalitha K Shankar1, Annick Van den Abbeele, Jeff Yap
1Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA. shankarl@mail.nih.gov
Abstract:
In the context of assessing tumor response, imaging tools have the potential to play a vital role in phase II and III treatment trials. If the imaging test is able to predict potential phase III success in a reliable fashion, it would be a useful tool in phase II trial design as it may provide for a more rapid and timely response assessment. The benefits and challenges of using anatomic imaging measures as well as the promising molecular imaging measures, primarily fluorodeoxyglucose-positron emission tomography, are discussed here. The general issues related to successful implementation of advanced imaging in the context of phase II treatment trials are discussed.
More Related Videos
Related Concept Videos
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...

